Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection



Status:Recruiting
Conditions:Skin Cancer, Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases, Oncology
Healthy:No
Age Range:Any
Updated:2/24/2019
Start Date:August 10, 2017
End Date:August 28, 2024
Contact:Amgen Call Center
Email:medinfo@amgen.com
Phone:866-572-6436

Use our guide to learn which trials are right for you!

A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients

A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC®
(Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic
Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in
Treated Patients


Inclusion Criteria:

- Patient has provided written informed consent

- Patient is an adult (≥ 18 years of age at the time of informed consent) with a
diagnosis of melanoma

- Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the
treatment of melanoma

Exclusion Criteria:

- Patient has a prior history of being a subject in an interventional clinical trial for
IMLYGIC
We found this trial at
7
sites
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Graz,
Click here to add this to my saved trials
?
mi
from
Jefferson City, MO
Click here to add this to my saved trials
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
?
mi
from
Murray, UT
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials